Comparative Pharmacology
Head-to-head clinical analysis: DARVON N versus ZIPAN 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON N versus ZIPAN 25.
DARVON-N vs ZIPAN-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak mu-opioid receptor agonist that produces analgesia by binding to opioid receptors in the central nervous system, altering the perception of and response to pain. Its metabolite norpropoxyphene has local anesthetic and sodium channel blocking effects, which may contribute to cardiac toxicity.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking serotonin reuptake into presynaptic neurons.
100 mg orally every 4 hours as needed for pain; maximum 600 mg per day.
25 mg orally twice daily
None Documented
None Documented
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours. Accumulation of norpropoxyphene on repeated dosing increases risk of toxicity.
Terminal elimination half-life: 6-8 hours in adults; may be prolonged (up to 12 hours) in elderly or patients with renal impairment (CrCl <30 mL/min).
Primarily renal (approximately 70% as unchanged drug and glucuronide conjugates); minor biliary/fecal elimination (25-30%).
Primarily renal excretion of unchanged drug (70-80%); fecal elimination accounts for 15-20% via biliary excretion; less than 5% as metabolites.
Category C
Category C
Opioid Analgesic
Opioid Analgesic